Tyrosine kinase inhibitors in pediatric malignancies.
Cancer Invest
; 25(7): 606-12, 2007.
Article
in En
| MEDLINE
| ID: mdl-17952738
ABSTRACT
Tyrosine kinase inhibitors have been used to treat adult cancers for over a decade. Since the discovery of imatinib mesylate (STI-571, Gleevec; Novartis), tyrosine kinase inhibitors have ushered in a new age of targeted therapy. Although the United States Food and Drug Administration has approved several kinase inhibitors for use in adult cancers, currently only imatinib mesylate is approved for use in children with cancer. This review highlights the mechanisms of tyrosine kinase inhibition, the potential role of tyrosine kinase pathways in the treatment of pediatric cancers, and the current status of pediatric clinical investigation of a spectrum of tyrosine kinase inhibitors for the treatment of childhood cancer.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Protein-Tyrosine Kinases
/
Protein Kinase Inhibitors
/
Neoplasms
Limits:
Child
/
Humans
Language:
En
Journal:
Cancer Invest
Year:
2007
Type:
Article
Affiliation country:
United States